225. 先天性腎性尿崩症 Congenital nephrogenic diabetes insipidus Clinical trials / Disease details


臨床試験数 : 15 薬物数 : 48 - (DrugBank : 18) / 標的遺伝子数 : 30 - 標的パスウェイ数 : 64

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-001591-30-DK
(EUCTR)
06/11/201709/03/2017 Treatment of congenital nephrogenic diabetes insipidus with riociguat or sildenafil Treatment of congenital nephrogenic diabetes insipidus with a guanylate cyclase stimulator, riociguat or a phosphodiesterase type 5 inhibitor, sildenafil Nephrogenic diabetes insipidus because of AVP2R-mutation
MedDRA version: 20.0;Level: LLT;Classification code 10012626;Term: Diabetes nephrogenic (excludes glycosuria);System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: Adempas
Product Name: Adempas
INN or Proposed INN: RIOCIGUAT
Other descriptive name: RIOCIGUAT
Trade Name: Viagra
Product Name: Viagra
INN or Proposed INN: SILDENAFIL
Odense University HospitalNULLNot Recruiting Female: no
Male: yes
2 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noDenmark